The EU Commission has authorised the use of two vaccines against influenza A (H1N1). The vaccines concerned are Focetria® (Novartis) and Pandemrix® (GlaxoSmithKline), and Pandemrix® is the one that will be used in Denmark.
The authorisation follows last week's recommendation by the European Medicines Agency (EMEA) to the European Commission to grant marketing authorisations for the vaccines.
In the factbox to the right, you can find the European Commission’s press release announcing the authorisation of the vaccines as well as our announcement regarding EMEA’s recommendation to authorise the vaccines.
For further information, please contact Chief Medical Officer Steffen Thirstrup, tel. +45 4488 9187 or +45 2246 7811.
Danish Medicines Agency, 1 October 2009